Drugs / Chondroitin sulphate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00604539 | Feb 2008 → Nov 2009 | osteoarthritis, synovitis | Bioiberica | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01226615 | Oct 2010 → Oct 2011 | osteoarthritis, knee | Bioiberica | Unknown | No outcome recorded |
| Phase 4 | NCT00669123 | — | osteoarthritis, knee, psoriasis | Bioiberica | Completed | Mixed |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT04095572 Comparator | Oct 2020 → Jun 2025 overdue | urinary tract infection | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| — | NCT05212259 Comparator | Oct 2022 → Sep 2023 | arthropathy | Vedic Lifesciences Pvt. Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chondroitin sulphate | “Chondroitin sulphate (CS)” NCT04095572 ↗ |
| Known as | Condrosan | “Chondroitin sulphate (Condrosan®)” NCT01226615 ↗1“Chondroitin sulphate (Condrosan)” NCT00604539 ↗ |
| Route | Oral | “800 mg (two capsules of 400 mg each) taken once a day for one year” NCT00604539 ↗ |